There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug ...

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Trade groups representing pharma distributors and generic/biosimilar industries express concerns over potential tariffs on ...

AAM submitted comments to CMS, highlighting the extent and ways in which Part D sponsors and their PBMs engage in practices that favor, intentionally or unintentionally, more expensive reference drugs ...

Makers of drugs and medical devices say the tariffs on goods from Canada, Mexico and China could have an outsized impact on ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The generic drug market faces higher costs and the looming ... to a material portion of the supply chain for generic and biosimilar medicines, and that's going to lead to both higher costs and ...